Brettoni, Cecilia
Muzzi, Alessandro
Rondini, Simona
Weynants, Vincent
Rossi Paccani, Silvia
Clinical trials referenced in this document:
Documents that mention this clinical trial
Sputum sample positivity for Haemophilus influenzae or Moraxella catarrhalis in acute exacerbations of chronic obstructive pulmonary disease: evaluation of association with positivity at earlier stable disease timepoints
https://doi.org/10.1186/s12931-021-01653-8
Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study
https://doi.org/10.1136/bmjopen-2013-004546
Ex-vivo RNA expression analysis of vaccine candidate genes in COPD sputum samples
https://doi.org/10.1186/s12931-023-02525-z
A prospective, observational cohort study of the seasonal dynamics of airway pathogens in the aetiology of exacerbations in COPD
https://doi.org/10.1136/thoraxjnl-2016-209023
Longitudinal profiling of the lung microbiome in the AERIS study demonstrates repeatability of bacterial and eosinophilic COPD exacerbations
https://doi.org/10.1136/thoraxjnl-2017-210408
Article History
Received: 19 January 2022
Accepted: 31 August 2023
First Online: 5 October 2023
Change Date: 29 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s12931-024-02826-x
Declarations
:
: All procedures were in accordance with the 1964 Declaration of Helsinki and its amendments. The study was approved by the Southampton and South West Hampshire Research Ethics Committee (11/H0502/9). Each participant provided written informed consent.
: Not applicable.
: CB, AM, SR, VW, and SRP are employees of GSK. AM, SR, SRP, and VW also hold shares in GSK. All authors declare no other financial and non-financial relationships and activities.